Posted by Michael Wonder on 23 Jan 2017
Ocular Therapeutix resubmits NDA for Dextenza for the treatment of ocular pain occurring after ophthalmic surgery
23 January 2017 - Ocular Therapeutix today announced that it has resubmitted a new drug application to the U.S. FDA for Dextenza (dexamethasone 0.4 mg insert) for the treatment of ocular pain occurring after ophthalmic surgery.
Dextenza is a product candidate administered by a physician as a bioresorbable intra-canalicular insert and designed for drug release to the ocular surface for up to 30 days.
